US4618577A
(en)
*
|
1983-02-09 |
1986-10-21 |
The Regents Of The University Of California |
Human-human hybridoma, CLNH5
|
CA1247538A
(en)
*
|
1982-05-21 |
1988-12-28 |
Mark C. Glassy |
Human-human hybridomas for solid tumors
|
DE3483054D1
(de)
*
|
1983-03-04 |
1990-10-04 |
Health Research Inc |
Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
|
US4939240A
(en)
*
|
1983-03-04 |
1990-07-03 |
Health Research, Inc. |
Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
|
US4613576A
(en)
*
|
1983-03-09 |
1986-09-23 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies to cancer cells
|
US4693966A
(en)
*
|
1983-03-11 |
1987-09-15 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
|
SE8401945L
(sv)
*
|
1983-04-08 |
1984-11-13 |
Kureha Chemical Ind Co Ltd |
Antikropp mot cancer i urinblasan hos menniska
|
WO1985002411A1
(en)
*
|
1983-11-25 |
1985-06-06 |
The University Of Melbourne |
Cell line and monoclonal antibody
|
NZ210867A
(en)
*
|
1984-01-31 |
1989-01-06 |
Litton Bionetics Inc |
Tumour-specific monoclonal antibodies, production thereof and use
|
DK144485A
(da)
*
|
1984-03-30 |
1985-10-01 |
Syntex Inc |
Monoklonale antistoffer
|
US4886745A
(en)
*
|
1984-03-30 |
1989-12-12 |
Syntex Inc. |
Monoclonal antibody specific for human basal cell surface antigen
|
JPS6133125A
(ja)
*
|
1984-07-25 |
1986-02-17 |
Morinaga & Co Ltd |
ヒト単クロ−ン性抗肺ガン細胞抗体
|
US4761377A
(en)
*
|
1984-10-15 |
1988-08-02 |
The Regents Of The University Of California |
Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
|
JPS61130300A
(ja)
*
|
1984-11-27 |
1986-06-18 |
ザ ボ−ド オブ トラステイ−ズ オブ ザ レランド スタンフオ−ド ジユニア ユニバ−シテイ |
ヒトモノクロ−ナル抗体
|
US5106746A
(en)
*
|
1985-05-22 |
1992-04-21 |
E. I. Du Pont De Nemours And Company |
Process for the in vitro immunization of human splenocytes against tumor associated antigens
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
JPH0655680B2
(ja)
*
|
1985-10-26 |
1994-07-27 |
萩原 義秀 |
悪性腫瘍用ヒトモノクロナル抗体複合剤
|
EP0222360A3
(en)
*
|
1985-11-12 |
1989-03-15 |
Biotherapeutics Inc. |
A method of producing a patient-specific cytotoxic reagent and composition
|
JPH0767388B2
(ja)
*
|
1986-01-13 |
1995-07-26 |
三菱化学株式会社 |
抗体産生細胞株の樹立方法
|
WO1991009135A1
(en)
*
|
1989-12-18 |
1991-06-27 |
Board Of Regents, The University Of Texas System |
Tumor-specific, cell surface-binding monoclonal antibodies
|
US5281710A
(en)
*
|
1990-08-01 |
1994-01-25 |
The Scripps Research Institute |
Dynemicin analogs: synthesis, methods of preparation and use
|
JPH04346792A
(ja)
*
|
1991-05-22 |
1992-12-02 |
Hagiwara Yoshihide |
抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするdna塩基配列
|
DE69222909T2
(de)
*
|
1991-08-16 |
1998-03-12 |
Toshiba Kawasaki Kk |
Monoklonaler Antikörper gegen ein Synaptophysin
|
AU747883B2
(en)
|
1997-08-15 |
2002-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
|
TWI290832B
(en)
|
1999-08-23 |
2007-12-11 |
Chugai Pharmaceutical Co Ltd |
Expression enhancer for HM1.24 antigen
|
AU7450600A
(en)
|
1999-10-01 |
2001-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
WO2002064159A1
(en)
|
2001-02-07 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for tumor in hematopoietic organs
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
ES2353496T3
(es)
|
2002-02-14 |
2011-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Productos farmacéuticos en solución que contienen anticuerpos.
|
WO2004019966A1
(ja)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質溶液製剤の安定化方法
|
JP5525118B2
(ja)
|
2002-09-11 |
2014-06-18 |
中外製薬株式会社 |
タンパク質精製方法
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
WO2005017155A1
(ja)
|
2003-06-18 |
2005-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーター
|
EP2311468B1
(en)
|
2003-08-08 |
2014-01-15 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
WO2005054467A1
(ja)
|
2003-12-03 |
2005-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
哺乳類βアクチンプロモーターを利用した発現系
|
JPWO2005056605A1
(ja)
|
2003-12-12 |
2007-12-06 |
中外製薬株式会社 |
3量体以上の受容体を認識する改変抗体
|
ES2353967T3
(es)
|
2004-07-09 |
2011-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-glipicano 3 .
|
EP2208783A1
(en)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
RU2446826C2
(ru)
|
2005-10-14 |
2012-04-10 |
Фукуока Юниверсити |
Агенты для подавления повреждения трансплантированных островков после трансплантации островков
|
WO2007055378A1
(ja)
|
2005-11-14 |
2007-05-18 |
Cell Signals Inc. |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
US20090269335A1
(en)
|
2005-11-25 |
2009-10-29 |
Keio University |
Therapeutic agent for prostate cancer
|
EP3135298B1
(en)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
EP2011870A4
(en)
|
2006-04-14 |
2010-09-15 |
Medical & Biol Lab Co Ltd |
MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
|
PL2047863T3
(pl)
|
2006-06-08 |
2014-01-31 |
Chugai Pharmaceutical Co Ltd |
Zapobieganie lub leczenie chorób zapalnych
|
AU2007259739B2
(en)
|
2006-06-14 |
2013-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for promoting the growth of hematopoietic stem cells
|
PE20081004A1
(es)
|
2006-07-13 |
2008-09-18 |
Chugai Pharmaceutical Co Ltd |
Agentes inductores de muerte celular
|
EP2047862B9
(en)
|
2006-07-21 |
2013-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Remedy for renal disease
|
DE602006013809D1
(de)
|
2006-07-24 |
2010-06-02 |
Facultad De Medicina Universid |
Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Adcc活性を増強させた抗体及びその製造方法
|
RU2537245C2
(ru)
|
2006-10-12 |
2014-12-27 |
Чугаи Сейяку Кабусики Кайся |
Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
|
EP2078731A4
(en)
|
2006-10-20 |
2012-08-01 |
Forerunner Pharma Res Co Ltd |
PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
|
WO2008081942A1
(ja)
|
2007-01-05 |
2008-07-10 |
The University Of Tokyo |
抗prg-3抗体を用いる癌の診断および治療
|
WO2008105560A1
(ja)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
抗grp78抗体を有効成分として含む医薬組成物
|
WO2009001840A1
(ja)
|
2007-06-25 |
2008-12-31 |
Forerunner Pharma Research Co., Ltd. |
ADCC活性又はCDC活性を有する抗Prominin-1抗体
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
RU2490025C2
(ru)
|
2007-10-02 |
2013-08-20 |
Чугаи Сейяку Кабусики Кайся |
Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
|
JP5620106B2
(ja)
|
2007-10-24 |
2014-11-05 |
株式会社糖鎖工学研究所 |
増強されたエフェクター機能を有するポリペプチド
|
AU2008321840B2
(en)
|
2007-11-14 |
2014-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
SG188134A1
(en)
|
2007-11-15 |
2013-03-28 |
Chugai Pharmaceutical Co Ltd |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
KR101595134B1
(ko)
|
2007-12-05 |
2016-02-17 |
추가이 세이야쿠 가부시키가이샤 |
소양증 치료제
|
KR101643005B1
(ko)
|
2007-12-05 |
2016-07-28 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
KR20100116179A
(ko)
|
2008-01-11 |
2010-10-29 |
고쿠리츠다이가쿠호우진 도쿄다이가쿠 |
항-cldn6 항체
|
NZ623716A
(en)
|
2008-04-11 |
2016-04-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2116261A1
(en)
|
2008-05-07 |
2009-11-11 |
Institut Pasteur |
Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
|
EP2283862B1
(en)
|
2008-06-02 |
2018-08-08 |
The University of Tokyo |
Combination treatment of cancer comprising anti-mfg-e8 antibody
|
CN102256623A
(zh)
|
2008-06-05 |
2011-11-23 |
独立行政法人国立癌症研究中心 |
神经浸润抑制剂
|
CA2728473A1
(en)
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
MX2011006908A
(es)
|
2008-12-26 |
2011-10-06 |
Univ Tokio |
Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7.
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
US8455249B2
(en)
|
2009-05-01 |
2013-06-04 |
The University Of Tokyo |
Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
US8815211B2
(en)
|
2010-02-10 |
2014-08-26 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
WO2011105573A1
(ja)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
抗icam3抗体およびその用途
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
PT2578231T
(pt)
|
2010-05-28 |
2022-12-02 |
Chugai Pharmaceutical Co Ltd |
Potenciador de resposta de células t antitumoral
|
MX2013004679A
(es)
|
2010-10-25 |
2014-02-20 |
Univ Minnesota |
Composicion terapeutica para el tratamiento de glioblastoma.
|
DK3404043T3
(da)
|
2010-10-29 |
2022-11-14 |
Perseus Proteomics Inc |
Anti-cdh3-antistof med høj internaliseringskapacitet
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
EP2749572A4
(en)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP3603671A3
(en)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
KR102168733B1
(ko)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
CN104220595A
(zh)
|
2012-04-04 |
2014-12-17 |
株式会社英仙蛋白质科学 |
抗cdh3(p-钙粘着蛋白)抗体的药剂偶联物
|
EP2876160B1
(en)
|
2012-07-06 |
2020-05-13 |
Kyoto Prefectural Public University Corporation |
Differentiation marker for and differentiation control for ocular cells
|
TWI606066B
(zh)
|
2012-09-27 |
2017-11-21 |
中外製藥股份有限公司 |
FGFR3 Fusion Gene and Its Targeted Medicine
|
JP6442404B2
(ja)
|
2013-06-11 |
2018-12-19 |
国立研究開発法人国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
EP3087986B1
(en)
|
2013-12-27 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Fgfr gatekeeper mutant gene and drug targeting same
|
JP6858559B2
(ja)
|
2014-08-20 |
2021-04-14 |
中外製薬株式会社 |
蛋白質溶液の粘度測定方法
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TW202339800A
(zh)
|
2015-02-27 |
2023-10-16 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
KR20190133005A
(ko)
|
2017-03-24 |
2019-11-29 |
젠야쿠코교가부시키가이샤 |
항 IgM/B 세포 표면 항원 이중 특이성 항체
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
EP3747469A4
(en)
|
2018-01-31 |
2022-03-23 |
Motokazu Kato |
THERAPEUTIC AGENT FOR ASTHMA CONTAINING AN IL-6 INHIBITOR
|
JPWO2020175689A1
(zh)
|
2019-02-28 |
2020-09-03 |
|
|
EP3957324A4
(en)
|
2019-04-17 |
2023-02-08 |
Hiroshima University |
THERAPEUTIC AGENT FOR UROLOGICAL CANCER CHARACTERIZED IN THAT IT IS ADMINISTERED WITH AN IL-6 INHIBITOR AND A CCR2 INHIBITOR IN COMBINATION
|
US20220227887A1
(en)
|
2019-06-11 |
2022-07-21 |
Ono Pharmaceutical Co., Ltd. |
Immunosuppressant
|
EP4134099A4
(en)
|
2020-04-06 |
2024-05-29 |
PhotoQ3 Inc. |
MEDICINES TO KILL TUMOR CELLS
|
MX2023000854A
(es)
|
2020-07-28 |
2023-02-15 |
Chugai Pharmaceutical Co Ltd |
Formulacion de jeringa precargada con aguja con protector de aguja que contiene nuevo anticuerpo modificado.
|
CA3192768A1
(en)
|
2020-08-27 |
2022-03-03 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
AU2022232856A1
(en)
|
2021-03-12 |
2023-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
CN118043031A
(zh)
|
2021-10-04 |
2024-05-14 |
诺华股份有限公司 |
表面活性剂稳定剂
|
KR20240011866A
(ko)
|
2021-12-01 |
2024-01-26 |
추가이 세이야쿠 가부시키가이샤 |
항체 함유 제제의 조제 방법
|